Medigus Expands Global Commercial Availability of MUSE™ Through Distribution Agreement With Izasa Hospital, S.L.U. in Spain
OMER, Israel, July 19, 2017 – Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced a distribution agreement in Spain with Izasa Hospital, S.L.U., a distributor of medical products in the hospital sector. The five year commercialization agreement will take effect July 1, 2017; Izasa Hospital, S.L.U. will be required to purchase a minimum of EUR 1.4 million of Medigus Ultrasonic Surgical Endostapler (MUSE™) equipment over the course of the agreement.
“About twenty-six percent of Europe’s population experience reflux on a weekly basis ; we will now be able to better address this prolific issue with the introduction of MUSE in Spain,” said Mr. Alfonso Garcia, General Manager of Izasa Hospital, S.L.U. “MUSE addresses an unmet need in long-term GERD care, and we feel that our customers and their patients will benefit from the use of this innovative treatment option.”
“The MUSE system offers a minimally invasive solution for gastroesophageal reflux disease (GERD), and we are excited to expand availability to Spain, an important development market for our organization, “ said Chris Rowland, Chief Executive Officer of Medigus. “We are looking forward to collaborating with Izasa Hospital to help provide patients and the healthcare community with innovative and advanced technologies that enhance patient care and outcomes.”
The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).
GERD, commonly referred to as acid reflux, is largely characterized by heartburn. Those who experience symptoms such as heartburn or regurgitation twice a week or more, may be at risk for persistent GERD.